Eliminating hypertension disparities in U.S. non-Hispanic black adults: current and emerging interventions.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
2
6
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
Hypertension in non-Hispanic black (NHB) adults in the United States has an earlier onset, higher prevalence, and increased severity compared with other racial/ethnic populations. Uncontrolled hypertension is responsible for the increased burden of cardiovascular disease (CVD) morbidity and mortality and decreased longevity in NHB adults. Unfortunately, eliminating the persistent hypertension-associated disparities and the white/black mortality gap, worsened by the COVID-19 pandemic, has been challenging. Overcoming the social determinants of health (SDOH), implementing therapeutic lifestyle changes (TLC), and using intensive guideline-directed medical therapy are required. Moreover, novel approaches, including community-based interventions and self-measured blood pressure (SMBP) monitoring, may mitigate U.S. disparities in hypertension. In this review, we discuss recent data regarding the U.S. NHB adult disparate hypertension control and CVD morbidity and mortality. We note current approaches to address disparities, such as TLC, evidence-based pharmacotherapy, community-based interventions and SMBP. Finally, we explore future research and initiatives to seek hypertension-related health equity. In the final analysis, longstanding, unacceptable hypertension and CVD morbidity and mortality in U.S. NHB adults must be addressed. Appropriate TLC and evidence-based pharmacotherapy benefit all populations, especially NHB adults. Ultimately, novel community-based interventions and SMBP may help overcome the SDOH that cause hypertension disparities.
Identifiants
pubmed: 37115906
doi: 10.1097/HCO.0000000000001040
pii: 00001573-202307000-00005
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
304-310Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke Statistics—2023 update: a report from the American Heart Association. Circulation 2023; 147:e125–136.
U.S. Department of Health and Human Services. Diversity and inclusion in clinical trials . National Institute of Minority Health and Health Disparities. https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html . [Accessed 27 January 2023]
Laffin LJ, Kaufman HW, Chen Z, et al. Rise in blood pressure observed among us adults during the COVID-19 pandemic. Circulation 2022; 145:235–237.
Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. JAMA 2020; 324:1190–1200.
Egan BM. Hypertension control among US adults, 2009 to 2012 through 2017 to 2020, and the impact of covid-19. Hypertension 2022; 79:1981–1983.
Woodruff RC, Tong X, Jackson SL, et al. Abstract 9853: trends in national death rates from heart disease in the United States, 2010–2020. Circulation 2022; 146:A9853.
Ferdinand K, Batieste T, Fleurestil M. Contemporary and future concepts on hypertension in African Americans: COVID-19 and beyond. J Natl Med Assoc 2020; 112:315–323.
Vaughan AS, Coronado F, Casper M, et al. County-level trends in hypertension-related cardiovascular disease mortality-United States, 2000 to 2019. J Am Heart Assoc 2022; 11:e024785.
Centers for Disease Control and Prevention. (28 February 2022). Chronic kidney disease basics. https://www.cdc.gov/kidneydisease/basics.html . [Accessed 27 January 2023]
Erickson KF, Worsley M, Winkelmayer WC. Fifty Years of a national program for the treatment of kidney failure. JAMA 2023; 329:205.
Yan G, Nee R, Scialla JJ, et al. Estimation of black-white disparities in CKD outcomes: comparison using the 2021 versus the 2009 CKD-EPI Creatinine Equations. Am J Kidney Dis 2022; 80:423–426.
Giudicelli GC, De Souza CM, Veronese FV, et al. Precision medicine implementation challenges for APOL1 testing in chronic kidney disease in admixed populations. Front Genet 2022; 13:1016341–11016341.
Powell-Wiley TM, Baumer Y, Baah FO, et al. Social determinants of cardiovascular disease. Circ Res 2022; 130:782–799.
Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC. Race, ethnicity, hypertension, and heart disease: JACC Focus Seminar 1/9. J Am Coll Cardiol 2021; 78:2460–2470.
Minhas AMK, Jain V, Li M, et al. Family income and cardiovascular disease risk in American adults. Sci Rep 2023; 13:279.
Collins SV, Hines AL. Stress reduction to decrease hypertension for black women: a scoping review of trials and interventions. J Racial Ethn Health Disparities 2022; 9:2208–2217.
Khan SU, Javed Z, Lone AN, et al. Social vulnerability and premature cardiovascular mortality among US counties, 2014 to 2018. Circulation 2021; 144:1272–1279.
Motairek I, Lee EK, Janus S, et al. Historical neighborhood redlining and contemporary cardiometabolic risk. J Am Coll Cardiol 2022; 80:171–175.
Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71:e127–e248.
Weston LJ, Kim H, Talegawkar SA, et al. Plant-based diets and incident cardiovascular disease and all-cause mortality in African Americans: a cohort study. PLOS Med 2022; 19:e1003863.
Sheehy S, Palmer JR, Cozier Y, et al. Vitamin D and risk of hypertension among black women. J Clin Hypertens 2023; 25:168–174.
Paluch AE, Bajpai S, Bassett DR, et al. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health 2022; 7:
Centers for Disease Control and Prevention. Best practices for heart disease and stroke: a guide to effective approaches and strategies. 2022; Atlanta, GA: Centers for Disease Control and Prevention,
Margolis KL, Bergdall AR, Crain AL, et al. Comparing pharmacist-led Telehealthcare and clinic-based care for uncontrolled high blood pressure: the Hyperlink 3 Pragmatic Cluster-Randomized Trial. Hypertension 2022; 79:2708–2720.
Takahashi EA, Schwamm LH, Adeoye OM, et al. An overview of telehealth in the management of cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2022; 146:e558–e568.
Khoong EC, Commodore-Mensah Y, Lyles CR, Fontil V. Use of self-measured blood pressure monitoring to improve hypertension equity. Curr Hypertens Rep 2022; 24:599–613.
Rubin R. Telemedicine rollbacks-why providing care across state lines is no longer as simple as it was early in the pandemic. JAMA 2022; 328:2291–2293.
McManus RJ, Little P, Stuart B, et al. HOME BP investigators. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomized controlled trial. BMJ 2021; 372:m4858.
Meador M, Hannan J, Roy D, et al. Accelerating use of self-measured blood pressure monitoring (SMBP) through clinical-community care models. J Community Health 2021; 46:127–138.
Cong M, Liu M, Ouyang J, et al. PCV45 the healthcare effects of the Ochsner Hypertension Digital Medicine Program. Value Health 2021; 24:S75.
Milani RV, Price-Haywood EG, Burton JH, et al. Racial differences and social determinants of health in achieving hypertension control. Mayo Clin Proc 2022; 97:1462–1471.
Ferdinand DP, Reddy TK, Wegener MR, et al. Text my BP MEDS Nola: a pilot study of text-messaging and social support to increase hypertension medication adherence. Am Heart J Cardiol Res Pract 2023; 26:100253.
Abel WM, Efird JT, Crane PB, et al. Use of coaching and technology to improve blood pressure control in black women with hypertension: pilot randomized controlled trial study. J Clin Hypertens 2022; 25:95–105.
Tajeu GS, Colvin CL, Hardy ST, et al. Prevalence, risk factors, and cardiovascular disease outcomes associated with persistent blood pressure control: the Jackson Heart Study. PLoS One 2022; 17:e0270675.
Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension 2022; 79:e1–e14.
Onakomaiya D, Cooper C, Barber A, et al. Strategies to improve medication adherence and blood pressure among racial/ethnic minority populations: a scoping review of the literature from 2017 to 2021. Curr Hypertens Rep 2022; 24:639–654.
Kim H, Shin J. Role of home blood pressure monitoring in resistant hypertension. Clin Hypertens 2023; 29:2.
Egan BM, Yang J, Rakotz MK, et al. Self-reported antihypertensive medication class and temporal relationship to treatment guidelines. Hypertension 2022; 79:338–348.
Soremekun O, Dib MJ, Rajasundaram S, et al. Genetic heterogeneity in cardiovascular disease across ancestries: insights for mechanisms and therapeutic intervention. Cambridge Prisms: Precision Medicine 2023; 1.
Kaze AD, Gao X, Musani SK, et al. Association of plasma endothelin-1 with blood pressure progression among Blacks: the Jackson Heart Study. Am Heart J 2022; 246:144–151.
Schlaich MP, Bellet M, Weber MA, et al. PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicenter, blinded, randomized, parallel-group, phase 3 trial. Lancet 2022; 400:1927–1937.
Ferdinand KC, Izzo JL, Lee J, et al. Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation 2019; 139:2098–2109.
Verma S, Dhingra NK, Butler J, et al. Empagliflozin in black versus white patients with heart failure: analysis of emperor-pooled. Circulation 2023; 147:101–104.
Michos ED, Reddy TK, Gulati M, et al. Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: an ASPC practice statement. Am J Prev Cardiol 2021; 8:100250.
Nasser SA, Arora N, Ferdinand KC. Addressing cardiovascular disparities in racial/ethnic populations: the blood pressure-lowering effects of SGLT2 inhibitors. Rev Cardiovasc Med 2022; 23:411.
Kesireddy V, Tan Y, Kline D, et al. The Association of Life's Simple 7 with Aldosterone among African Americans in the Jackson Heart Study. Nutrients 2019; 11:955.
Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's essential 8: updating and enhancing the American Heart Association's construct of Cardiovascular Health: a presidential advisory from the American Heart Association. Circulation 2022; 146:e18–e43.
Brewer LPC, Bowie J, Slusser JP, et al. Religiosity/spirituality and cardiovascular health: the American Heart Association Life's simple 7 in African Americans of the Jackson Heart Study. J Am Heart Assoc 2022; 11:e024974.
Kho A, Daumit GL, Truesdale KP, et al. The National Heart Lung and Blood Institute disparities elimination through coordinated interventions to prevent and control heart and lung disease alliance. Health Serv Res 2022; 57:20–31.
CDC. (16 December 2022). About Million hearts® 2027: Million hearts®. Centers for Disease Control and Prevention. https://millionhearts.hhs.gov/about-million-hearts/index.html . [Accessed 27 January 2023]
Centers for Disease Control and Prevention. Fixed-dose combination antihypertensive medications coverage by State Medicaid and Medicaid managed care organizations. 2022; Atlanta, GA: Centers for Disease Control and Prevention, U.S Department of Health and Human Services,
SMBP coverage insights: Medicaid | Ama - American medical association. (28 February 2022). https://www.ama-assn.org/system/files/smbp-coverage-medicaid-may-2022.pdf . [Accessed 2 February 2023]